Hengchi Yu1, Yaqun Zhao1, Yazhuo Zhang2,3, Liyong Zhong4. 1. Department of Endocrinology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, PR China. 2. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, PR China. 3. Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, PR China. 4. Department of Endocrinology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, PR China. zhongliyong@126.com.
Abstract
PURPOSE: Acromegaly is a rare disease caused by chronic hypersecretion of growth hormone, which leads to multiple comorbidities and reduced life expectancy. The objective of this study was to characterize the serum metabolic profiles of acromegaly patients and identify metabolic biomarkers using metabolomics. METHODS: Twenty-nine active acromegaly patients and age- and sex-matched normal controls were recruited. Serum samples were collected, and serum metabolites were analyzed using gas chromatography-mass spectrometry coupled with a series of multivariate statistical analyses. RESULTS: The orthogonal projections to latent structures-discriminate analysis (OPLS-DA) model identified and validated significant metabolic differences between individuals with acromegaly and normal controls (R2Y = 0.908 and Q2Y = 0.601). Compared with normal controls, acromegaly patients had elevated levels of 5-aminovaleric acid, glyceric acid, L-dithiothreitol, dihydrocoumarin, N-acetyl-L-glutamic acid, gluconic acid, and monoolein (P < 0.05) and reduced serum levels of D-erythronolactone, taurine, carbamoyl-aspartic acid, and mucic acid (P < 0.01). Furthermore, glyceric acid and taurine possessed higher area under the receiver operating characteristic curve values (AUC values, 0.914 and 0.931, respectively), suggesting an excellent clinical ability to distinguish acromegaly patients from normal controls. Pathway analysis revealed that the pentose phosphate pathway and the taurine and hypotaurine metabolic pathway are significant pathways (P = 0.002 and 0.004, respectively). CONCLUSIONS: Metabolic activity is significantly altered in the serum of individuals with active acromegaly. Glyceric acid and taurine may be considered potential biomarkers for distinguishing acromegaly patients from normal controls.
PURPOSE:Acromegaly is a rare disease caused by chronic hypersecretion of growth hormone, which leads to multiple comorbidities and reduced life expectancy. The objective of this study was to characterize the serum metabolic profiles of acromegalypatients and identify metabolic biomarkers using metabolomics. METHODS: Twenty-nine active acromegalypatients and age- and sex-matched normal controls were recruited. Serum samples were collected, and serum metabolites were analyzed using gas chromatography-mass spectrometry coupled with a series of multivariate statistical analyses. RESULTS: The orthogonal projections to latent structures-discriminate analysis (OPLS-DA) model identified and validated significant metabolic differences between individuals with acromegaly and normal controls (R2Y = 0.908 and Q2Y = 0.601). Compared with normal controls, acromegalypatients had elevated levels of 5-aminovaleric acid, glyceric acid, L-dithiothreitol, dihydrocoumarin, N-acetyl-L-glutamic acid, gluconic acid, and monoolein (P < 0.05) and reduced serum levels of D-erythronolactone, taurine, carbamoyl-aspartic acid, and mucic acid (P < 0.01). Furthermore, glyceric acid and taurine possessed higher area under the receiver operating characteristic curve values (AUC values, 0.914 and 0.931, respectively), suggesting an excellent clinical ability to distinguish acromegalypatients from normal controls. Pathway analysis revealed that the pentose phosphate pathway and the taurine and hypotaurine metabolic pathway are significant pathways (P = 0.002 and 0.004, respectively). CONCLUSIONS: Metabolic activity is significantly altered in the serum of individuals with active acromegaly. Glyceric acid and taurine may be considered potential biomarkers for distinguishing acromegalypatients from normal controls.
Authors: Robert W McGarrah; Scott B Crown; Guo-Fang Zhang; Svati H Shah; Christopher B Newgard Journal: Circ Res Date: 2018-04-27 Impact factor: 17.367
Authors: Daniel Stoessel; Claudia Schulte; Marcia C Teixeira Dos Santos; Dieter Scheller; Irene Rebollo-Mesa; Christian Deuschle; Dirk Walther; Nicolas Schauer; Daniela Berg; Andre Nogueira da Costa; Walter Maetzler Journal: Front Aging Neurosci Date: 2018-03-05 Impact factor: 5.750
Authors: Gudmundur Johannsson; Martin Bidlingmaier; Beverly M K Biller; Margaret Boguszewski; Felipe F Casanueva; Philippe Chanson; Peter E Clayton; Catherine S Choong; David Clemmons; Mehul Dattani; Jan Frystyk; Ken Ho; Andrew R Hoffman; Reiko Horikawa; Anders Juul; John J Kopchick; Xiaoping Luo; Sebastian Neggers; Irene Netchine; Daniel S Olsson; Sally Radovick; Ron Rosenfeld; Richard J Ross; Katharina Schilbach; Paulo Solberg; Christian Strasburger; Peter Trainer; Kevin C J Yuen; Kerstin Wickstrom; Jens O L Jorgensen Journal: Endocr Connect Date: 2018-02-26 Impact factor: 3.335